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SUMMARY – Glioblastoma multiforme (GBM) is the most common and most aggressive ma-
lignant primary brain tumor in humans. Clinically useful molecular markers that help predict response 
to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 
(47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, 
 primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 
1:250) were used to evaluate neovascularization. Statistical analysis showed negative correlation 
 between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter sur-
vival), but there was no correlation between neovascularization determined by CD105 in GBM and 
patient survival. Thus, significant individual predictors of longer survival were lower expression of 
CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results  obtained 
suggested the possible role of CD44 in the progression and tumor neovascularization of GBM.
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Introduction
Glioblastoma multiforme (GBM) is the most 
common malignant primary brain tumor in adults. The 
mean progression-free survival is just over 6 months. It 
is widely acknowledged that the incurable nature of 
GBM is primarily attributable to the infiltrative 
growth of the cancer. Treatment with surgical resec-
tion, chemotherapy and radiation is invariably fol-
lowed by tumor recurrence1.
The prognosis of GBM patients is based on deter-
mining the prognostic value of various factors, includ-
ing tumor markers. CD44 is a transmembrane glyco-
protein that regulates cell growth, survival, differentia-
tion and migration, and is thereby widely considered 
to be involved in carcinogenesis. CD44 is expressed in 
multiple forms, the most common being CD44 stan-
dard (CD44). As this protein has been examined in 
many cancer types, we employed immunohistochemi-
cal analysis of CD44 in GBM and correlated the ex-
pression of CD44 with neovascularization and sur-
vival of GBM patients. The identification of tumor 
markers such as CD44 could be of prognostic value in 
GBM patients and could help set up an individual 
treatment plan for these patients, with the goal of pro-
longing survival2-4.
Also significant in GBM is angiogenesis, whereby 
endoglin (CD105) (accessory receptor for the trans-
forming growth factor beta, TGF-β) is used as a mark-
er which can determine density of the newly formed 
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tumor blood vessels and can be used to quantify angio-
genesis. These factors are especially significant for 
 research of future therapeutic options based on angio-
genesis, which have been proven useful in GBM 
 patients so far3.
Materials and Methods
Patients
Archival materials of 55 patients having undergone 
surgery for primary glioblastoma at the Department of 
Neurosurgery between January 2003 and December 
2009 were used in the study. Data on patient survival 
were obtained from Cancer Registry of the Croatian 
Public Health Institute. Karnofsky score and survival 
time (number of days from day of operation to day of 
death) were established for every patient. Only pa-
tients with all clinical data available and with adequate 
histopathological findings were included in the study; 
patients treated with radiotherapy or chemotherapy, as 
well as patients with recurrent GBM were excluded 
from the analysis.
Immunohistochemistry
Paraffin blocks with GBM from every patient who 
matched the mentioned criteria were separated out of 
the archive. The material was processed by a standard 
histological method which includes fixation of tissue 
in 10% neutral buffered formalin and embedding into 
paraffin blocks, cutting into 5-µm thickness, deparaf-
finizing and staining with the standard hematoxylin 
and eosin method (HE).
Primary antibody for CD44 (dilution 1:50, Dako, 
Denmark) and primary antibody for endoglin 
(CD105) (dilution 1:250, Dako, Denmark) for deter-
mining microvascular density (MVD) were used in the 
study. Neovascularization determined by CD105 was 
marked as MVD/105. Immunohistochemical analysis 
was performed by the labeled streptavidin biotin 
(LSAB) method as a visualization system on a DAKO 
TechMate TM (Dako, Denmark) automated machine 
for immunohistochemical staining with the use of the 
microwave streptavidin immunoperoxidase (MSIP) 
protocol. Results of immunohistochemical analysis for 
CD44 marker were analyzed by light microscope and 
shown semiquantitatively by determining the percent-
age of immunoreactive tumor cells in the total selected 
cross section of tumor tissue. The endoglin (CD105) 
marker served to assess density of the newly formed 
tumor blood vessels. MVD was measured in the most 
active area of tumor neovascularization, which was de-
termined by viewing histologic tumor cross sections 
under small magnification (X40) using Olympus CX 
41 microscope in three non-overlapping large fields of 
view (X400). Every separated lumen surrounded by 
endoglin positive cells or, in the absence of lumen, ev-
ery endoglin positive cell was considered to be a newly 
formed blood vessel. The mean value of three measure-
ments was used on data processing.
Statistical analysis
Statistical analysis was performed by using the 
STATISTICA ver. 6.0 (StatSoft Inc., Tulsa, OK, 
USA) statistical package with the use of descriptive 
statistics. Regression analysis (parametric and non-
parametric, depending on the type of distribution) was 
used to determine correlation of single variables, while 
the χ2-test or Fisher exact test was used to compare 
qualitative variables among subgroups. Outcomes re-
lated to survival were analyzed using survival life tables 
and Cox models of proportional hazards. Kruskal- 
-Wallis test was also performed. The level of statistical 
significance was set at p<0.05.
Results
Patient characteristics
Among 55 GBM patients there were 26 (47.3%) 
women and 29 (52.7%) men. According to age, they 
were divided into those aged ≤65 (n=29; 52.7%) and 
>65 (n=26; 47.3%). The mean patient Karnofsky score 
was 75.45 and mean survival 183.82 days.
CD44 and MVD/CD105 expression
The mean CD44 expression in glioblastoma tu-
mors was 64.91 (range 40.00-90.00, SD 17.23) (Fig. 
1). The mean expression of endoglin and mean density 
of newly formed blood vessels in glioblastomas (MVD/
CD105) was 15.64 (range 3.67-52.33, SD 8.91).
Descriptive statistical analysis of patients accord-
ing to age, survival, CD44, MVD/CD105 and Kar-
nofsky score is illustrated in Table 1. Statistical analy-
sis of parameters yielded a number of statistically sig-
nificant correlations (Table 2). There was negative cor-
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relation between CD44 and survival (greater expression 
of CD44 correlated with shorter survival; p=0.023) 
and positive correlation between Karnofsky score and 
survival (higher Karnofsky score correlated with lon-
ger survival; p=0.018). A relation was also demonstrat-
ed between greater expression of CD44 and female sex 
(p=0.039).
Patients were grouped according to the level of 
CD44 expression (0-45, 46-75 and 76-100), whereby 
no statistically significant difference was found be-
tween their results (p=0.066 was the borderline result). 
Analysis according to sex and age did not show sig-
nificant differences among the groups of CD44 ex-
pression (sex differences were at borderline level, 
p=0.066).
Different CD44 groups were also analyzed accord-
ing to particular parameters, i.e. age, MVD/CD105, 
Karnofsky score and survival (Table 3). There was no 
statistically significant difference, except for the rela-
tion of CD44 and survival (p=0.0117), i.e. the mean 
survival in the CD44 group 0-45 was 185.67 days, in 
CD44 group 46-75 it was 234.42 days, and in the 
CD44 group 76-100 it was 118.74 days. Significant 
differences were only recorded in survival, which was 
longest in the 46-75 group (mean, 234.42 days) and 
significantly shorter in the 76-100 group (mean, 
118.74 days).
Accordingly, it should be noted that significant in-
dividual predictors of longer survival were lower CD44 
expression (beta=-0.39; p=0.004), higher Karnofsky 
score (beta=0.26; p=0.045) and female sex (beta=0.31; 
p=0.017), while the strongest individual predictor was 
CD44 expression. Correlation between CD44 expres-
sion and density of newly formed blood vessels (MVD/
CD105) was not demonstrated; CD44 expression cor-
related statistically significantly with patient survival, 
but there was no correlation between density of newly 
formed blood vessels (MVD/CD105) in GBM and 
patient survival (Table 4).
Discussion
There are numerous studies of the prognostic value 
of CD44, which have different results. CD44 is known 
to be a transmembrane glycoprotein, the various iso-
forms of which are encoded based on alternative RNA 
cutting, and the most numerous isoform variant is the 
standard type CD44. CD44 expression in tissues has 
primarily been detected by immunohistochemistry 
(IHC) and reverse transcription polymerase chain re-
action (RT-PCR)5-12. It is important to understand the 
complexities of this molecule given its ability to func-
tion at the center of multiple signaling highways and 
to act as a tumor microenvironment sensory tool2,5,6. 
Fig. 1. Strong CD44 activity in the majority  
of glioblastoma cells (magnification X400).
Table 1. Characteristics of glioblastoma multiforme patients: age, length of survival, CD44, MVD/CD105  
and Karnofsky score (N=55)
Arithmetic mean SD Min Max Percentile25th Median 75th 
Age (yrs) 62.58 9.24 47.00 77.00 55.00 63.00 71.00
Survival (days) 183.82 133.16 7.00 512.00 87.00 151.00 263.00
MVD/CD105 15.64 8.91 3.67 52.33 9.33 13.00 21.00
CD44 64.91 17.23 40.00 90.00 50.00 65.00 80.00
Karnofsky score 75.45 20.89 40.00 100.00 60.00 80.00 90.00
MVD = microvascular density
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However, CD44-mediated biology goes beyond the 
complexity of a molecule that either promotes or in-
hibits cancer because CD44 regulates cellular process-
es that can do both. Decades of research have shown 
that CD44 participates in major oncogenic signaling 
networks and complexes with oncogens that promote 
every aspect of tumor progression. Conversely, CD44 
signaling also mediates contact inhibition and inhibits 
cell invasion and angiogenesis. CD44 is extremely sen-
sitive to changes in the microenvironment, and al-
though much is known about its biology, its reaction to 
changing extra- and intracellular conditions is still the 
subject of active research7.
Aside from the participation of CD44 in matrix 
adhesion, activation and lymphocyte navigation, 
wound healing, growth promotion, cellular survival 
and migration, it also participates in tumor growth and 
metastasizing3-5,8,13. The importance of CD44 is shown 
in tumorigenesis, since CD44 mediates the interaction 
of extracellular matrix and intracellular cytoskeleton, 
and shows interaction with growth factors and matrix 
metalloproteinases, thus activating signaling pathways 
which may stimulate tumor growth and suppression of 
apoptosis5,6. Changes in CD44 molecule expression 
have been noticed in various types of tumor, such as 
breast tumor, soft tissue sarcomas, as well as neuroblas-
tomas6-8.
Research into the role of CD44 in the develop-
ment of neoplasms has shown contradicting results. 
Thus, colorectal carcinoma showed increased CD44 
expression, whereas in prostate carcinoma, there was a 
correlation between lower CD44 expression and meta-
static progression9,10,14. Similar to that, some studies 
noted that overexpression of CD44 was related to bet-
Table 2. Correlation coefficients among age, length of survival (days) and particular clinical parameters





coefficient 1.000 0.234 0.120 -0.036 0.072 0.022
p  0.085 0.383 0.793 0.602 0.846
n 55 55 55 55 55 55
CD44
Correlation 
coefficient 0.234 1.000 -0.091 0.022 -0.306 0.241
p 0.085  0.508 0.874 0.023 0.039
n 55 55 55 55 55 55
Karnofsky score
Correlation 
coefficient 0.120 -0.091 1.000 -0.242 0.318 -0.093
p 0.383 0.508  0.075 0.018 0.437
n 55 55 55 55 55 55
Age
Correlation 
coefficient -0.036 0.022 -0.242 1.000 -0.189 0.142
p 0.793 0.874 0.075  0.167 0.212
n 55 55 55 55 55 55
Survival (days)
Correlation 
coefficient 0.072 -0.306 0.318 -0.189 1.000 0.087
p 0.602 0.023 0.018 0.167  0.438
n 55 55 55 55 55 55
Sex*
Correlation 
coefficient 0.022 0.241 -0.093 0.142 0.087 1.000
p 0.846 0.039 0.437 0.212 0.438 .
n 55 55 55 55 55 55
*Kendall’s tau_b; MVD = microvascular density; figures in bold are statistically significant
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ter prognosis, whereas others showed that lower CD44 
expression contributed to tumor invasion14-16.
We found negative correlation between CD44 and 
survival in GBM patients by statistical analysis, i.e. in-
creased CD44 expression was related to decreased sur-
vival, supporting the potential prognostic significance 
of that marker in this tumor. Otherwise, there was 
positive correlation between Karnofsky score and sur-
vival, i.e. higher Karnofsky score correlated with longer 
survival in GBM patients1,2,17.
The potential influence of CD44 on tumor growth 
and expansion could be exerted in many ways. CD44 
probably stimulates proliferation, motility and/or in-
vasiveness of tumor cells (it probably recruites and ac-
tivates matrix metalloproteinases attached to cell sur-
face)1,2,18. It is also possible that CD44 promotes tumor 




mean SD Min Max
 Percentile
25th Median 75th 
Age
0-45 12 65.17 8.89 47.00 77.00 57.25 67.50 70.75
46-75 24 60.50 9.51 48.00 77.00 51.75 60.00 68.75
76-100 19 63.58 9.00 49.00 75.00 55.00 65.00 72.00
MVD/CD105
0-45 12 14.56 8.10 6.00 32.00 8.42 11.50 21.58
46-75 24 14.19 5.96 3.67 24.67 10.00 12.50 20.08
76-100 19 18.16 11.94 6.67 52.33 8.78 13.00 22.67
Karnofsky 
score
0-45 12 74.17 22.75 40.00 100.00 52.50 70.00 100.00
46-75 24 78.75 19.85 40.00 100.00 62.50 85.00 97.50
76-100 19 72.11 21.49 40.00 100.00 50.00 80.00 90.00
Survival (days)*
0-45 12 185.67 142.00 7.00 477.00 74.00 173.50 271.25
46-75 24 234.42 142.93 23.00 512.00 126.00 208.50 370.50
76-100 19 118.74 82.98 13.00 352.00 59.00 121.00 151.00
Kruskal 
Wallis test df p
Age 2.00 2 0.367
MVD/CD105 0.89 2 0.641
Karnofsky score 1.10 2 0.577
Survival (days) 8.19 2 0.017
*Kendall’s tau_b; MVD = microvascular density; figures in bold are statistically significant
Table 4. Linear regression model of survival prognosis
 
Nonstandardized coefficient Standardized coefficient t p
95% CI
B Standard error Beta Lower Upper
Age -2.34 1.81 -0.16 -1.30 0.201 -5.97 1.29
Female sex* 83.03 33.56 0.31 2.47 0.017 15.60 150.47
MVD/CD105 1.60 1.87 0.11 0.86 0.396 -2.15 5.36
CD44* -3.03 1.00 -0.39 -3.03 0.004 -5.05 -1.02
Karnofsky score* 1.65 0.80 0.26 2.05 0.045 0.04 3.26
95% CI = 95% confidence interval; *Kendall’s tau_b; MVD = microvascular density; figures in bold are statistically significant
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angiogenesis by regulating endothelial cells and/or re-
cruiting, i.e. activating inflammatory cells. Besides 
that, CD44 has been shown to be involved in other 
mechanisms of carcinogenesis as well, i.e. noticeable is 
the role of brain tumor stem cells that are involved in 
tumor progression, whereby CD44 could be a contrib-
uting factor19,20.
On the other hand, several studies showed that 
lower CD44 expression correlated with lower survival 
in patients with different types of cancer, and some au-
thors demonstrated it in GBM patients as well21,22. 
Therefore, although higher CD44 expression has been 
frequently found to correlate with worse tumor prog-
nosis, lower CD44 values may also indicate that ma-
lignant cells are more resistant to chemotherapeutic 
agents.
Special importance of the role of angiogenesis in 
tumors should be borne in mind, thus also in GBM 
which is highly vascularized15,20,23-29. Angiogenesis has 
an important role in the progression of this tumor. Tu-
mor angiogenesis is regulated by proangiogenic and 
antiangiogenic factors produced by tumor, as well as by 
the surrounding and infiltrating host cells24,25. Tumor 
blood vessels and normal blood vessels are distin-
guished by their organization, vascular patterns and 
density of newly formed small blood vessels. The ad-
vantage of endoglin lies in its expression that is only 
evident in endothelial cells which are proliferating, but 
not in normal blood vessels or tumor cells26,27. Sica et 
al.28 studied neovascularization in peritumoral areas, as 
well as CD105 and nestin expression besides density 
of small blood vessels, in order to assess their possible 
prognostic value. They found tumor neoangiogenesis 
to develop in peritumoral GBM tissue, whereby peri-
cytes contributed closely and CD105-MVD had a 
prognostic value in the areas at longer distance from 
tumor edge28. Our results of determining blood vessel 
density by analyzing CD105/MVD showed no corre-
lation between CD105/MVD expression and patient 
survival.
Since angiogenesis plays a major role in GBM 
growth, there are treatment options based on angio-
genesis which have shown clinical efficacy in GBM 
patients24. The administration of the potentially the-
rapeutic antiangiogenic agents [such as anti-vascular 
endothelial growth factor VEGF/VEGF receptor 
(VEGFR) agents] has shown clinical benefits in GBM 
patients30-33.The possibility of inhibiting signaling to 
the angiogenic factors VEGF and hepatocyte growth 
factor (HGF) by targeting CD44v6 variant is a very 
important approach to antitumor treatment20,26,30-33.
In conclusion, the results of our study showed neg-
ative correlation between CD44 and survival. Moni-
toring and research of CD44 is related to the possible 
treatment modalities in GBM patients, since CD44 
can be the target of antiangiogenic therapy.
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Sažetak
PROGNOSTIČKA VRIJEDNOST EKSPRESIJE CD44 I NEOVASKULARIZACIJE  
ODREĐENE ENDOGLINOM (CD105) U BOLESNIKA S GLIOBLASTOMOM
J. Mihić, K. Rotim, M. Vučić, I. Hude Dragičević, M. Borić i L. Lugović-Mihić
Glioblastom multiforme (GBM) je najčešći i najagresivniji maligni primarni tumor mozga u ljudi. Postoje tek rijetki 
molekularni biljezi koji su klinički korisni te pomažu u predviđanju odgovora na terapiju i u prognozi bolesti. Istraživanje je 
provedeno kod 55 bolesnika s GBM, 26 (47,3%) žena i 29 (52,7%) muškaraca, prosječne dobi od 62,58 godina. U imunohi-
stokemijskoj analizi je za procjenu neovaskularizacije korišteno primarno antitijelo prema CD44 (razrjeđenje 1:50) i primar-
no antitijelo prema endoglinu (CD105) (razrjeđenje 1:250). Statistička analiza je pokazala negativnu korelaciju između 
CD44 i preživljenja (p=0,023) (veća ekspresija CD44 je korelirala s kraćim preživljenjem), ali nije bilo korelacije između 
neovaskularizacije (određene putem CD105) kod GBM i preživljenja ovih bolesnika. Tako su značajni pojedinačni predik-
tori dužeg preživljenja bili niža ekspresija CD44 (p=0,004), veći Karnofskyjev zbir (p=0,045) i ženski spol (p=0,017). Dobi-
veni rezultati ukazuju na moguću ulogu CD44 u progresiji i tumorskoj neovaskularizaciji kod GBM.
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